Siplizumab

Siplizumab
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Siplizumab is a monoclonal antibody designed for the treatment of conditions involving the immune system, such as psoriasis, graft-versus-host disease (GVHD), and certain types of cancer. It specifically targets the CD2 receptor found on the surface of T cells, which are a type of white blood cell involved in immune responses. By binding to these cells, Siplizumab modulates the immune system's activity to prevent the pathological processes associated with autoimmune diseases and transplant rejection.

Mechanism of Action

Siplizumab functions by binding to the CD2 receptor on T cells. This interaction inhibits the activation and proliferation of T cells, which are critical components in the development of autoimmune responses and in the rejection of transplanted organs. The inhibition of T cell activity helps in reducing inflammation and the immune response against the body's own tissues or against the transplanted organ.

Clinical Uses

Siplizumab has been investigated in several clinical trials for its effectiveness and safety in treating autoimmune diseases and preventing transplant rejection. It has shown promise in conditions such as:

• Psoriasis
• Graft-versus-host disease (GVHD)
• Prevention of rejection in organ transplantation

Side Effects

As with any immunosuppressive agent, the use of Siplizumab can lead to increased susceptibility to infections. Other potential side effects include:

• Anemia
• Neutropenia
• Thrombocytopenia
• Infusion-related reactions

Patients receiving Siplizumab require careful monitoring for signs of infection and other adverse effects associated with immunosuppression.

Development and Approval

The development of Siplizumab has involved multiple phases of clinical trials to assess its safety and efficacy. As of the last update, it has not yet received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for general medical use. Ongoing research and clinical trials continue to evaluate its potential applications and long-term outcomes.

See Also

• Monoclonal antibodies
• Immunosuppression
• Autoimmune disease
• Transplant rejection